Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Inclusion Criteria: * • Adults aged greater than or equal to (\>=) 18 years on the day of signing the informed consent form. * • Confirmed diagnosis of SCD of any genotype. * • Experienced 1 to 12 VOCs requiring a visit to a medical facility and treatment with parenteral opioids or a parenteral nonsteroidal anti-inflammatory drug within the 12 months before Screening. * • HU Regimen: * a. On stable and well-tolerated Hydroxyurea (HU) regimen for at least 30 days before Screening. * or * b. HU was discontinued or refused (eg, due to concern of side effects or lack of effect). Exclusion Criteria: * • Absolute neutrophil count less than (\<) 2.5 ×10\^9 cells/Litre at Screening or Baseline (Week 1 Day 1). * • If on SCD preventive medication, dose is not stable in the 30 days before Screening.